Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
 BACK TO LIST

Laboratory Report

Patient
Name: Forster, , Jason,
DOB: 10-MAR-1983 (Age: 42)
Gender: male
Address:
437 Martin trail
M20 Heatherville (United Kingdom)
ID: 2238-744377-7 (ECI)
Report
Date: 16-JAN-2022
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Cornbrook Medical Practice
City Road 204
M3 3 Manchester (United Kingdom)
Specimen
Collected: 16-JAN-2022

Chemistry

Test 16-JAN-2022 Reference Range Unit
Cholesterol [Mass/volume] in Serum or Plasma 236.9 H 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 146.8 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 185.6 H 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 21.9 L 40 - 160 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows dyslipidemia with elevated total and LDL cholesterol, and markedly low HDL cholesterol. These findings indicate increased cardiovascular risk. Clinical correlation and consideration of lifestyle modification and/or lipid-lowering therapy are recommended.